Freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== Overdose == There have been cases of death with dimethyltryptamine (DMT). In terms of extrapolated human lethal dose based on animal studies and human case reports, the lethal dose of ayahuasca relative to a typical recreational or entheogenic dose is estimated to be 50-fold.
Maternal behavior: Female rats given oxytocin antagonists after giving birth do not exhibit typical maternal behavior. By contrast, virgin female sheep show maternal behavior toward foreign lambs upon cerebrospinal fluid infusion of oxytocin, which they would not do otherwise. Oxytocin is involved in the initiation of human maternal behavior, not its maintenance; for example, it is higher in mothers after they interact with unfamiliar children rather than their own. Human ingroup bonding: Oxytocin can increase positive attitudes, such as bonding, toward individuals classified as "in-group" members, whereas other individuals become classified as "out-group" members. Oxytocin has also been implicated in lying when lying would prove beneficial to other in-group members. In a study where such a relationship was examined, it was found that when individuals were administered oxytocin, rates of dishonesty in the participants' responses increased for their in-group members when a beneficial outcome for their group was expected. Both of these examples show the tendency of individuals to act in ways that benefit those considered to be members of their social group, or in-group. Decreased oxytocin and receptor expression has been associated with aggressive behavior in aggressive-impulsive disorders. Oxytocin is not only correlated with individuals' preferences to associate with members of their own group, but it is also evident during conflicts between members of different groups.
== Pathophysiology == IKr (hERG) blockade On EKG, the QT interval represents the summation of action potentials in cardiac muscle cells. QT prolongation therefore results from action potential prolongation, which can be caused by an increase in inward current through sodium or calcium channels, or a decrease in outward current through potassium channels. By binding to and inhibiting the "rapid" delayed rectifier potassium current protein, IKr, which is encoded by the hERG gene, certain drugs are able to decrease the outward flow of potassium ions and extend the length of phase 3 myocardial repolarization, which is reflected as QT prolongation. hERG trafficking inhibition A number of drugs that cause QT prolongation does not directly block hERG, but reduces the trafficking of the mature protein to the surface of the cell. This includes probucol, which appears to enhance the intercellular degradation of hERG; and several cardiac glycosides, which reduces trafficking due to decreased intracellular potassium. Some drugs such as ketoconazole both directly disrupt the Ikr channel and reduce its trafficking. Growth factors A number of antineoplastic drugs inhibit VEGF or PDGF signaling. As those growth factors are also important for the survival and renewal of cardiomyocytes, they exhibit toxicity to these cells. With some such agents, the result is QT prongation.
== External links == "Understanding the RNA World". Exploring Life's Origins. Exploring Origins Project. Ferris, James P. "The Formation of the RNA World". The New York Center for Studies of the Origins of Life, Rensselaer Polytechnic Institute. Archived from the original on March 1, 2012. Altman, Sidney (2001). "The RNA World". NobelPrize.org. Nobel Media. Kuska, Robert (June 2002). "A World Apart" (PDF). HHMI Bulletin. Howard Hughes Medical Institute. pp. 14–19. Archived (PDF) from the original on 2004-05-22. Cech, Thomas R. (2004). "Exploring the New RNA World". NobelPrize.org. Nobel Media. Sutherland JD (April 2010). "Ribonucleotides". Cold Spring Harbor Perspectives in Biology. 2 (4) a005439. doi:10.1101/cshperspect.a005439. PMC 2845210. PMID 20452951. "The Origins of the RNA World". YouTube. Library of Congress. August 5, 2016.
Sources: en.wikipedia.org
=== Biosynthesis === Prostacyclin is produced in endothelial cells, which line the walls of arteries and veins, from prostaglandin H2 (PGH2) by the action of the enzyme prostacyclin synthase. Although prostacyclin is considered an independent mediator, it is called PGI2 (prostaglandin I2) in eicosanoid nomenclature, and is a member of the prostanoids (together with the prostaglandins and thromboxane). PGI2, derived primarily from COX-2 in humans, is the major arachidonate metabolite released from the vascular endothelium. This is a controversial point, some assign COX 1 as the major prostacyclin producing cyclooxygenase in the endothelial cells of the blood vessels. The series-3 prostaglandin PGH3 also follows the prostacyclin synthase pathway, yielding another prostacyclin, PGI3. The unqualified term 'prostacyclin' usually refers to PGI2. PGI2 is derived from the ω-6 arachidonic acid. PGI3 is derived from the ω-3 EPA.
== History == The 1950s to 1970s represented the golden age of antibiotic discovery, where countless new classes of antibiotics were discovered to treat previously incurable diseases such as tuberculosis and syphilis. However, since that time the discovery of new classes of antibiotics has been almost nonexistent, and represents a situation that is especially problematic considering the resiliency of bacteria shown over time and the continued misuse and overuse of antibiotics in treatment. Already in 1940, in their letter to the editor of Nature journal, Abraham and Chain identified the enzyme penicillinase as responsible for the deactivation of penicillin in penicillin-resistant bacteria. This discovery was the first step in understanding the mechanisms of microbial resistance to β-lactam antibiotics. The phenomenon of antimicrobial resistance caused by overuse of antibiotics was predicted as early as 1945 by Alexander Fleming who said "The time may come when penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant man may easily under-dose himself and by exposing his microbes to nonlethal quantities of the drug make them resistant." Without the creation of new and stronger antibiotics an era where common infections and minor injuries can kill, and where complex procedures such as surgery and chemotherapy become too risky, is a very real possibility. Antimicrobial resistance can lead to epidemics of enormous proportions if preventive actions are not taken.
=== Fight Song === In 2009, Santa Fe College adopted a fight song. "Saints Forever" was performed for the first time on Tuesday, April 21, 2009, between softball games in Gainesville. The song was a collaboration between Chris Sharp, the college's director of bands, and Ryan B. Leverone, a Santa Fe College student.
Sources: en.wikipedia.org
The four-stage plan specifies roles and responsibilities of governments and industry partners. At this point, the country was at level two, dubbed "Keeping Australia moving", after going through a preparation and planning phase. The federal government announced the cutting of fuel excise by 50%, along with a three-month pause on road user charges for trucks. Singapore and Australia have signed an agreement to keep their energy trade flowing, with Singapore diversifying the origins of its supplies of crude oil.
The first problems to occur in obese children are usually emotional or psychological. Obese children often experience bullying by their peers. Some are harassed or discriminated against by their own family. Stereotypes abound and may lead to low self-esteem and depression.
Chemical Garden at The Periodic Table of Videos (University of Nottingham) Chemical Gardens (Colloidal garden) at (http://chemistry-chemists.com) Chemobrionics (COST Action linking European research groups to stimulate innovative and high-impact interdisciplinary scientintific research on chemical gardens) Chemobrionics Database
Together with his close collaborator Richard DiMarchi (Indiana University) he discovered and validated the novel drug class of dual and triple gut hormone co-agonists for the treatment of obesity and diabetes, and was also a co-founder of a biotechnology company MB2 LLC that was successfully acquired by Novo Nordisk in 2015. These new drugs simultaneously target several receptors and reduce body weight and blood sugar with unprecedented efficacy. Several of these compounds are in clinical trials for the treatment of diabetes and obesity and one representative of this drug class, the GIP/GLP1 receptor dual agonist Tirzepatide (Mounjaro, Eli Lilly and Company) was FDA approved for diabetes in 2022. Tschöp and DiMarchi more recently went on to discover and validate another class of drug candidates by engineering peptide to deliver steroid/small molecules to selected cell populations. In 2022, Tschöp was a candidate to succeed Heinz Engl as rector of the University of Vienna; however, he ultimately withdrew his application.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.